This figure shows Overall Survival (OS) as a function of in vitro sensitivity to drugs administered as second-line treatment in the LRF CLL4 study

  1. Sensitive in DiSC Assay to drug received = solid line

  2. Intermediate assay result = hashed line

  3. Resistant in DiSC Assay to treatment received = hashed/dotted line

Patients who received drugs to which their malignant cells were sensitive in the DiSC Assay achieved superior overall survival compared with patients receiving drugs to which their cells were resistant in the DiSC Assay.  Clearly, CLL patients should not receive treatment with assay-resistant drugs.


Matutes E, Bosanquet AG, Wade R, et al, The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry. Leukemia (2013) 27, 507–510; doi:10.1038/leu.2012.209.  Link to full text.


Back to Home Page